Advertisement

Nitric Oxide, Systemic Inflammatory Response Syndrome and Circulatory Shock

  • C. Thiemermann
Conference paper

Abstract

The medical syndrome of shock can be defined as a “progressive failure of the circulation to provide blood and oxygen to vital organs of the body”. In clinical practice, the key symptom of shock is a severe fall in blood pressure which is often associated with the dysfunction or failure of several important organs including lung, kidney, liver and brain. The most common cause of shock is the contamination of blood with bacteria (bacteremia), viruses, fungi or parasites, resulting in systemic infection and ultimately shock (septic shock). Other causes of shock include severe hemorrhage (hemorrhagic shock), trauma (traumatic shock), failure of the heart to maintain a sufficient cardiac output (cardiogenic shock), interruption of the innervation of blood vessels (neurogenic shock) and severe allergic reactions (anaphylactic shock). Septic shock, regardless of its aetiology, is defined as sepsis (systemic response to infection) with hypotension despite adequate fluid replacement, resulting in impaired tissue perfusion and oxygen extraction (Parrillo, 1990). The definition of septic shock is independent of the presence or absence of a multiple organ dysfunction syndrome (MODS), which is defined as impaired organ function such that homeostasis cannot be maintained without intervention (Baue, 1993). Primary MODS is a direct result of a well-defined insult to a specific organ.

Keywords

Nitric Oxide Septic Shock Systemic Inflammatory Response Syndrome Multiple Organ Dysfunction Syndrome Amino Guanidine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arkovitz MS, Wispe JR, Garcia VF, Szabo C (1996) Selective inhibition of the inducible isoform of nitric oxide synthase prevents pulmonary transvascular flux during acute endotoxemia. J Pediatr Surg 31: 1009 – 1015PubMedCrossRefGoogle Scholar
  2. Baue AE (1993) The multiple organ or systems failure syndrome. In: Schlag G, Redl H (eds) Pathophysiology of shock, sepsis and organ failure, Springer, Berlin, pp 1004 – 1018Google Scholar
  3. Billiar TR, Curran RD, Harbrecht BG, Stuehr DJ, Demetris AJ, Simmons RL (1990) Modulation of nitrogen oxide synthesis in vivo: NG-monomethyl-L-arginine inhibits endotoxin-induced nitrite/nitrate biosynthesis while promoting hepatic damage. J Leukoc Biol 48: 565 – 569PubMedGoogle Scholar
  4. Boje KM (1996) Inhibition of nitric oxide synthase attenuates blood-brain barrier disruption during experimental meningitis. Brain Res 720: 75 – 83PubMedCrossRefGoogle Scholar
  5. Booke M, Hinder F, McGuire R, Traber LD, Traber DL (1996a) Nitric oxide synthase inhibition versus norepinephrine for the treatment of hyperdynamic sepsis in sheep. Crit Care Med 24: 835 – 844CrossRefGoogle Scholar
  6. Booke M, Hinder F, McGuire R, Traber LD, Traber DL (1996b) Nitric oxide synthase inhibition versus norepinephrine in ovine sepsis: effects on regional blood flow. Shock 5: 362 – 370CrossRefGoogle Scholar
  7. Carnigie PR, Fellows FCI, Symington GR (1977) Urinary excretion of methylarginineGoogle Scholar
  8. in human disease. Metabolism 26:531–537Google Scholar
  9. Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL, Sweetland MA, Lancaster JR, Williamson JR, McDaniel ML (1992) Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41: 552 – 558PubMedCrossRefGoogle Scholar
  10. Dinerman JL, Lowenstein CJ, Snyder SH (1993) Molecular mechanism of nitric oxide regulation: potential relevance to cardiovascular disease. Circ Res 73: 217 – 222PubMedGoogle Scholar
  11. Faraci WS, Nagel AA, Verdries KA, Vincent LA, Xu H, Nichols LE, Labasi JM, Salter ED, Pettipher ER (1996) 2-Amino-4-methylpyridine as a potent inhibitor of inducible NO synthase activity in vitro and in vivo. Br J Pharmacol 119:1101–1108Google Scholar
  12. Garvey EP, Oplinger J A, Furfine ES, Kiff RJ, Laszlo F, Whittle BJR, Knowles RG (1997) 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric oxide synthase in vitro and in vivo. J Biol Chem 272:4959–4963Google Scholar
  13. Garvey PE, Oplinger JA, Tanoury GJ, Sherman PA, Fowler M, Marshall S, Marmon MF, Paith JE, Furfine ES (1994) Potent and selective inhibition of human nitric oxide synthases. Inhibition by non-amino acid isothioureas. J Biol Chem 269: 26669 – 26676PubMedGoogle Scholar
  14. Gross SS, Stuehr DJ, Aisaka K, Jaffe EA, Levi R, Griffith OW (1990) Macrophage and endothelial nitric oxide synthesis: cell-type selective inhibition by NG-aminoargi- nine, NG-nitroarginine and NG-methyl-arginine. Biochem Biophys Res Commun 170: 96 – 103PubMedCrossRefGoogle Scholar
  15. Julou-Schaeffer G, Gray GA, Fleming I, Schott C, Parratt JR, Stoclet JC (1990) Loss of vascular responsiveness induced by endotoxin involves the L-arginine pathway. Am J Physiol 259: H1038 – 1043PubMedGoogle Scholar
  16. Kilbourn RG, Gross SS, Jubran A, Adams J, Griffith OW, Levi R, Lodato RF (1990) NG-methyl-L-arginine inhibits tumour necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 87: 3629 – 3632PubMedCrossRefGoogle Scholar
  17. Kilbourn RG, Juburan A, Gross SS, Griffith OW, Levi R, Adams J (1990) Reversal of endotoxin-mediated shock by NG-monomethyl-L-arginine, an inhibitor of nitric oxide synthesis. Biochem Biophys Res Commun 172: 1132 – 1138PubMedCrossRefGoogle Scholar
  18. Lorente JA, Landin L, De Pablo R, Renes E, Liste D (1993) L-arginine pathway in the sepsis syndrome. Crit Care Med 21: 1287 – 1295PubMedCrossRefGoogle Scholar
  19. Loscalzo J, Welsch G (1995) Nitric oxide and its role in the cardiovascular system. Proj Cardiovascular Dis 38: 87 – 104CrossRefGoogle Scholar
  20. MacMicking JD, Nathan C, Horn G (1995) Altered responses to bacterial infection and endo toxic shock in mice lacking inducible nitric oxide synthase. Cell 82: 641 – 650CrossRefGoogle Scholar
  21. Meyer J, Lentz CW, Stothert JC, Traber LD, Herndon DN, Traber DL (1994) Effects of nitric oxide synthesis inhibition in hyperdynamic endotoxemia. Crit Care Med 22: 306 – 312PubMedCrossRefGoogle Scholar
  22. Moncada S, Higgs A (1993) The L–arginine–nitric oxide pathway. N Eng J Med 329: 2202 – 2212Google Scholar
  23. Moore WM, Webber RK, Jerome GM, Tjoeng FS, Misko TP, Currie MD (1994) L-N6- (l-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase. J Med Chem 37: 3886 – 3888PubMedCrossRefGoogle Scholar
  24. Morris SM, Billiar TR (1994) New insights into the regulation of inducible nitricoxide synthase. Am J Physiol 266: E829-E839 Nathan C (1992)Google Scholar
  25. Nitric oxide as a secretory product of mammalian cells. FASEB J 6: 3051–3064Google Scholar
  26. Nathanson C, Hoffmann WD, Suffredini EF, Eichacker PQ, Danner RL (1994) Selected treatment strategies for septic shock based on proposed mechanism of pathogenesis. Ann Intern Med 120: 771 – 783Google Scholar
  27. Park KS, Lee HW, Hong SY (1988) Determination of methylated amino acids in human serum by high-performance liquid chromatography. J Chromatography 440: 225 – 230CrossRefGoogle Scholar
  28. Parillo JE (1990) Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction and therapy. Ann Intern Med 113:227–242 Petros A, Bennett D, Vallance P (1991) Effect of nitric oxide synthase inhibitors onGoogle Scholar
  29. hypotension in patients with septic shock. The Lancet 338:1557–1558 Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P (1994) Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 28: 34–39Google Scholar
  30. Preiser JC, Vincent JL (1996) Nitric oxide involvement in septic shock: Do human beings behave like rodents In: Vincent JL (ed) 1996 Yearbook of Intensive Care and Emergency Medicine Springer, Berlin, pp 358 – 365Google Scholar
  31. Rees DD (1995) Role of nitric oxide in the vascular dysfunction in septic shock. Biochem Soc Trans 23: 1025 – 1029PubMedGoogle Scholar
  32. Rees DD, Cellek S, Palmer RMJ, Moncada S (1990) Dexamethasone prevents the induction of nitric oxide synthase and the associated effects on the vascular tone: an insight into endotoxic shock. Biochem Biophys Res Commun 173: 541 – 547PubMedCrossRefGoogle Scholar
  33. Robertson FM, Offner PJ, Ciceri DP, Becker WK, Pruitt BA Jr (1994) Detrimental hemodynamic effects of nitric oxide synthase inhibition in septic shock. Arch Surg 129: 149 – 155PubMedGoogle Scholar
  34. Ruetten H, Southan GJ, Abate A, Thiemermann C (1996) Attenuation of the multiple organ dysfunction caused by endotoxin by l-amino-2-hydroxy-guanidine, a potent inhibitor of inducible nitric oxide synthase. Br J Pharmacol 118: 261 – 270PubMedGoogle Scholar
  35. Ruetten H, Southan GJ, Abate A, Thiemermann C (1996) Attenuation of the multiple organ dysfunction caused by endotoxin by l-amino-2-hydroxy-guanidine, a potent inhibitor of inducible nitric oxide synthase. Br J Pharmacol 118: 261 – 270PubMedGoogle Scholar
  36. Seo HG, Fujiwara N, Kaneto H, Asashi M, Fujii J, Taniguchi N (1996) Effect of the nitric oxide synthase inhibitor, S-ethyl-isothiourea, on cultured cells and cardiovascular functions of normal and lipopolysaccharide-treated rabbits. J Biochem 119: 553 – 558PubMedGoogle Scholar
  37. Southan G, Szabo C, Thiemermann C (1995) Isothioureas: potent inhibitors of nitricoxide synthases with variable isoform selectivity. Br J Pharmacol 114: 510 – 516PubMedGoogle Scholar
  38. Southan GJ, Szabo C (1996) Selective pharmacological inhibition of distinct nitricoxide synthase isoforms. Biochem Pharmacol 51: 383 – 394PubMedCrossRefGoogle Scholar
  39. Southan GJ, Szabo C, O’Conner MP, Salzman AC, Thiemermann C (1996) Amidines are potent inhibitors of constitutive and inducible nitric oxide synthases: Preferential inhibition of the inducible isoform. Eur J Pharmacol 291: 311 – 318Google Scholar
  40. Sprong RC, Aarsman CJM, Oirschot JFLM, Asbeck BS (1997) Dimethylthiourea protects rats against gram–negative sepsis and decreases tumour necrosis factor and nuclear factor KB activity. J Lab Clin Med 129:470–481 Strohmeier W, Werner ER, Redl H, Wachter H, Schlag G (1995) Plasma nitrate and pteridine levels in experimental bacteremia in baboons. Pteridines 6: 8 – 11Google Scholar
  41. Szabo C, Southan G, Thiemermann C (1994) Beneficial effects and improved survival in rodent models of septic shock with S-methyl-isothiourea sulfate, a novel, potent and selective inhibitor of inducible nitric oxide synthase. Proc Natl Acad Sci USA 91: 12472 – 12476PubMedCrossRefGoogle Scholar
  42. Szabo C, Thiemermann C (1995) Regulation of the expression of the inducible isoform of nitric oxide synthase. Adv Pharmacol 34: 113 – 154PubMedCrossRefGoogle Scholar
  43. Thiemermann C (1994) The role of L-arginine: nitric oxide pathway in circulatory shock. Adv Pharmacol 28: 45 – 79PubMedCrossRefGoogle Scholar
  44. Thiemermann C (1994) The role of L-arginine: nitric oxide pathway in circulatory shock. Adv Pharmacol 28: 45 – 79PubMedCrossRefGoogle Scholar
  45. Thiemermann C, Vane JR (1990) Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharide in the rat. Eur J Pharmacol 182: 591 – 595PubMedCrossRefGoogle Scholar
  46. Walder CE, Thiemermann C, Vane JR (1991) The involvement of endothelium - derived relaxing factor in the regulation of renal cortical blood flow in the rat. Br J Pharmacol 102: 967 – 973PubMedGoogle Scholar
  47. Walker TA, Curtis SE, King-VanVlack CE, Chapler CK, Vallet B, Cain SM (1995) Effects of nitric oxide synthase inhibition on regional hemodynamics and oxygen transport in endotoxic dogs. Shock 4: 415 – 420PubMedGoogle Scholar
  48. Waurick R, Bone HG, Meyer J, Booke M, Meissner A, Prien T, Van Aken H (1997) Haemodynamic effects of dopexamine and nitric oxide synthase inhibition in healthy and endotoxaemic sheep. Eur J Pharmacol 333: 181 – 186PubMedCrossRefGoogle Scholar
  49. Wei X, Charles IG, Smith A (1995) Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 375: 408 – 411PubMedCrossRefGoogle Scholar
  50. Wolff DJ, Lubeskie A (1995) Aminoguanidine is an isoform-selective, mechanism-based inactivator of nitric oxide synthase. Arch Biochem Biophys 316: 290 – 301PubMedCrossRefGoogle Scholar
  51. Wu CC, Chen SJ, Szabo C, Thiemermann C, Vane JR (1995) Aminoguanidine attenuates the delayed circulatory failure and improves survival in rodent models of endotoxic shock. Br J Pharmacol 114: 1666 – 1672PubMedGoogle Scholar
  52. Wu CC, Ruetten H, Thiemermann C (1996) Comparison of the effects of aminoguanidine and NG-nitro-L-arginine methylester on the multiple organ dysfunction caused by endotoxaemia in the rat. Eur J Pharmacol 300: 99 – 104PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • C. Thiemermann

There are no affiliations available

Personalised recommendations